deltatrials
Completed PHASE3 NCT00034944

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Sponsor: Merck Sharp & Dohme LLC

Conditions Major Depressive Disorder
Interventions Comparator: placebo MK0869, aprepitant
Updated 8 times since 2017 Last updated: May 2, 2017 Started: Jan 24, 2002 Primary completion: Dec 17, 2003 Completion: Dec 17, 2003

This PHASE3 trial investigates Major Depressive Disorder and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2017 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.